Outsourcing

Articles

With numerous biologics set to come off patent soon and the percentage of new therapeutics based on biomolecules growing, demand for contract manufacturing in the biopharma space is heating up.

Will CMOs Provide Sufficient Capacity for Growing Biologics Demand?

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

Data from BioPlan Associates’ 10th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production suggest that the interest in disposable devices has begun to extend to biopharma operations beyond basic single-use bags and connectors.

Disposable Applications in Demand by Biopharma

Recipharm has invested EUR 32 million ($43 million) in its Wasserburg, Germany site to expand lyophilization capacity.

Recipham to Expand Lyophilization Capacity in Germany

Ronald A. Rader is senior director, Technical Research, at BioPlan Associates.

Advances in techniques and single-use systems are revolutionizing vaccine manufacturing.

Bioprocessing Advances in Vaccine Manufacture

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Industry experts share their views on the outsourcing model and the current and future direction of contract chemical API manufacturing.

Gaining Insights on Contract Chemical API Manufacturing An Industry Roundtable

A CMO perspective on the CMO-client partnership.

Making the Best of a Bad CMO-Client Relationship

External manufacturing plays a crucial role in pharmaceutical companies’ supply strategy. The author examines market trends for the captive and merchant global market for active pharmaceutical ingredients and intermediates.

A Shifting Landscape for the Global API Market

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report.

Approvals of new drugs are on an upward swing, but only a few CMOs are benefiting.

Drug Approval Trends Don't Extend to CMOs

Is the contract-only CMO an endangered species?

Contract Manufacturing Services